CK Life Sciences' Sequencio Therapeutics Presents Latest Cancer Vaccine Advancements at AACR

Sequencio showcases five research abstracts highlighting promising preclinical data across multiple vaccine modalities and targets.

Mar. 31, 2026 at 10:37am

Got story updates? Submit your updates here. ›

Sequencio Therapeutics, a subsidiary of CK Life Sciences, announced that five research abstracts will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations showcase significant advancements in next-generation cancer vaccine technologies based on Sequencio's proprietary TrueHLA™ Epitope-to-Efficacy™ translational design framework, highlighting robust immunogenicity and anti-tumor activity across multiple targets and modalities in preclinical models.

Why it matters

Sequencio's cancer vaccine pipeline represents a promising approach to developing the next wave of immunotherapies, leveraging rational, data-driven vaccine design to potentially improve upon current limitations of cancer vaccines. The AACR presentations underscore the scientific merit and progress of Sequencio's programs, which the company is now prioritizing for IND-enabling studies and early-stage clinical development through strategic partnerships.

The details

Sequencio's five AACR 2026 presentations cover a range of vaccine candidates, including those targeting p53 neoantigens, IGF1R, B7-H3, TROP2, and Claudin-6. The data demonstrate that Sequencio's rationally designed vaccines can induce robust humoral and cellular immune responses, as well as significant anti-tumor activity, in preclinical models. Building on this foundation, Sequencio is now focused on advancing its most promising programs towards the clinic.

  • The AACR Annual Meeting 2026 will take place from April 17-22, 2026 in San Diego, USA.
  • Sequencio's five research abstracts will be presented on April 21, 2026.

The players

Sequencio Therapeutics Company Limited

A subsidiary of CK Life Sciences Int'l., (Holdings) Inc. that is focused on developing next-generation cancer vaccine technologies.

CK Life Sciences Int'l., (Holdings) Inc.

A Hong Kong-listed company engaged in healthcare research and development, with a focus on cancer vaccines, RNA therapeutics, and pain management solutions.

Dr. Melvin Toh

Vice President & Chief Scientific Officer of CK Life Sciences, who oversees Sequencio's cancer vaccine pipeline and research efforts.

Got photos? Submit your photos here. ›

What they’re saying

“Sequencio's cancer vaccine pipeline continues to advance with strong momentum. Our AACR 2026 presentations underscore both the scientific promise of our vaccines and the disciplined execution driving their progress. We look forward to building on this foundation as we advance next‑generation immunotherapies for patients.”

— Dr. Melvin Toh, Vice President & Chief Scientific Officer of CK Life Sciences

What’s next

Sequencio is prioritizing its most promising vaccine programs for IND-enabling studies, with the goal of accelerating select candidates into early-stage clinical development through strategic partnerships and global collaboration.

The takeaway

Sequencio's innovative approach to cancer vaccine development, leveraging its proprietary TrueHLA™ Epitope-to-Efficacy™ platform, has yielded promising preclinical results across multiple modalities. As the company advances its pipeline towards the clinic, these advancements could pave the way for more effective and personalized cancer immunotherapies.